Tag: YolTech Therapeutics

YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia...

SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsYolTech Therapeutics

REGENCELL DEADLINE TUESDAY JUNE 23rd: Bragar Eagel & Squire, P.C. Reminds Regencell Bioscience Holdings Limited (NASDAQ:RGC) Investors They Have Until June 23rd to Contact...

HCI Group Enters the Tokenized Real-World Assets Market with Pilot Project Mirroring Returns of Specific Participations in HCI’s Catastrophe XOL Reinsurance Programs

Hankook Tire Puts Performance to the Test at Autobahn Country Club

Tag: YolTech Therapeutics

YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us